DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Information source: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Anemia; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous/Nonmalignant Condition; Unspecified Adult Solid Tumor, Protocol Specific

Intervention: darbepoetin alfa (Drug); epoetin alfa (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Jonsson Comprehensive Cancer Center

Official(s) and/or principal investigator(s):
John A. Glaspy, MD, MPH, Principal Investigator, Affiliation: Jonsson Comprehensive Cancer Center

Summary

RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy. It is not yet known whether darbepoetin alfa is more effective than epoetin alfa in treating patients with anemia. PURPOSE: Randomized phase III trial to compare the effectiveness of darbepoetin alfa with that of epoetin alfa in treating anemia in patients who are receiving chemotherapy for cancer.

Clinical Details

Official title: A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Primary outcome: Compare Efficacy of darbepoetin alfa with Epoetin Alfa as measured by the incidence of red blood cell transfusions.

Detailed description: OBJECTIVES: Primary

- Compare the efficacy of darbepoetin alfa vs epoetin alfa for anemia in patients with

non-myeloid malignancies receiving chemotherapy. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to screening hemoglobin concentration (less than 10. 0 g/dL vs 10. 0-11. 0 g/dL) and type of concurrent chemotherapy (platinum-based vs non-platinum-based). Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive darbepoetin alfa subcutaneously (SC) every other week for 12

weeks (i. e., on weeks 1, 3, 5, 7, 9, and 11).

- Arm II: Patients receive epoetin alfa SC once weekly for 12 weeks. Patients are

followed at 1 and 3 weeks . PROJECTED ACCRUAL: A total of 600 patients (300 per treatment arm) will be accrued for this study within 6 months.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of a non-myeloid malignancy

- Currently receiving or planning to receive at least 8 weeks of cyclic cytotoxic

chemotherapy

- Hemoglobin no greater than 11. 0 g/dL

- 18 and over

- ECOG 0-2

- Bilirubin less than 2 times upper limit of normal (ULN)

- Creatinine less than 2 times ULN

- Negative pregnancy test

- Fertile patients must use effective contraception

- HIV negative

- More than 30 days since prior darbepoetin alfa or epoetin alfa

- More than 30 days since prior participation in investigational device or drug trials

Exclusion Criteria:

- The following diagnoses are excluded:

- Acute myeloid leukemia

- Chronic myeloid leukemia

- Acute lymphoblastic leukemia

- Hairy cell leukemia

- Burkitt's lymphoma

- Lymphoblastic lymphoma

- other primary hematologic disorder that would cause anemia (e. g., sickle cell anemia)

- angina

- congestive heart failure

- New York Heart Association class III or IV heart disease

- hypertension

- cardiac arrhythmia

- other unstable or uncontrolled disease or condition that would affect cardiac

function

- pregnant or nursing

- known seizure disorder

- known sensitivity to study agents

- clinically significant inflammatory disease (e. g., rheumatoid arthritis or Crohn's

disease)

- confirmed neutralizing antibodies to epoetin alfa

- other disorder that would preclude study compliance or giving informed consent

- other concurrent epoetin alfas

- prior randomization to this study

- other concurrent investigational agents or procedures

Locations and Contacts

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California 90095, United States
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: August 2003
Last updated: August 2, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017